Research progress on posttransplant lymphoproliferative disease after lung transplantation
-
摘要: 移植后淋巴组织增生性疾病(PTLD)是肺移植术后可致死性并发症，与年龄、免疫抑制水平、爱泼斯坦-巴尔病毒(EBV)感染等密切相关。降低免疫抑制水平、利妥昔单抗治疗、T细胞免疫治疗是其常见的治疗手段。随着肺移植在中国的迅速发展，肺移植术后PTLD也引起高度关注。本文就肺移植术后发生PTLD的危险因素、病理分型、临床表现、诊断、治疗、预后和预防做一综述，旨在为肺移植术后PTLD发生、发展的早期监测和管理提供参考。
-
关键词:
- 肺移植 /
- 慢性移植肺功能障碍(CLAD) /
- 移植后淋巴组织增生性疾病(PTLD) /
- 爱泼斯坦-巴尔病毒(EBV) /
- 免疫抑制 /
- 利妥昔单抗 /
- 移植物抗宿主病(GVHD) /
- 闭塞性细支气管炎综合征
Abstract: Posttransplant lymphoproliferative disease (PTLD) is a fatal complication after lung transplantation, which is intimately associated with age, immunosuppression level and Epstein-Barr virus (EBV) infection, etc. Reducing immunosuppression level, rituximab therapy and T cell immunotherapy are common treatments for PTLD. With the rapid development of lung transplantation in China, PTLD after lung transplantation has attracted widespread attention. This article reviews the risk factors, pathological types, clinical manifestations, diagnosis, treatment, prognosis and prevention of PTLD after lung transplantation, aiming to provide reference for early monitoring and management of the incidence and progression of PTLD. -
[1] Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis[J]. N Engl J Med, 1986, 314(18): 1140-1145. DOI: 10.1056/NEJM198605013141802. [2] CHAMBERS DC, CHERIKH WS, HARHAY MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1042-1055. DOI: 10.1016/j.healun.2019.08.001. [3] COSTA J, BENVENUTO LJ, SONETT JR. Long-term outcomes and management of lung transplant recipients[J]. Best Pract Res Clin Anaesthesiol, 2017, 31(2): 285-297. DOI: 10.1016/j.bpa.2017.05.006. [4] CHAMBERS DC, CHERIKH WS, GOLDFARB SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation[J]. J Heart Lung Transplant, 2018, 37(10): 1169-1183. DOI: 10.1016/j.healun.2018.07.020. [5] RIZVI SMH, AAGNES B, HOLDAAS H, et al. Long-term change in the risk of skin cancer after organ transplantation: a population-based nationwide cohort study[J]. JAMA Dermatol, 2017, 153(12): 1270-1277. DOI: 10.1001/jamadermatol.2017.2984. [6] BENNETT D, FOSSI A, REFINI RM, et al. Posttransplant solid organ malignancies in lung transplant recipients: a single-center experience and review of the literature[J]. Tumori, 2016, 102(6): 574-581. DOI: 10.5301/tj.5000557. [7] DHARNIDHARKA VR, WEBSTER AC, MARTINEZ OM, et al. Post-transplant lymphoproliferative disorders[J]. Nat Rev Dis Primers, 2016, 2: 15088. DOI: 10.1038/nrdp.2015.88. [8] DIERICKX D, HABERMANN TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6): 549-562. DOI: 10.1056/NEJMra1702693. [9] ROMERO S, MONTORO J, GUINOT M, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation[J]. Leuk Lymphoma, 2019, 60(1): 142-150. DOI: 10.1080/10428194.2018.1474462. [10] SAMANT H, VAITLA P, KOTHADIA JP. Post transplant lymphoproliferative disorders[M]. Treasure Island (FL): StatPearls Publishing, 2021. [11] FERLA V, ROSSI FG, GOLDANIGA MC, et al. Biological difference between Epstein-Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact[J]. Front Oncol, 2020, 10: 506. DOI: 10.3389/fonc.2020.00506. [12] PETERS AC, AKINWUMI MS, CERVERA C, et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience[J]. Transplantation, 2018, 102(9): 1553-1562. DOI: 10.1097/TP.0000000000002146. [13] LUSKIN MR, HEIL DS, TAN KS, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder[J]. Am J Transplant, 2015, 15(10): 2665-2673. DOI: 10.1111/ajt.13324. [14] LEYSSENS A, DIERICKX D, VERBEKEN EK, et al. Post-transplant lymphoproliferative disease in lung transplantation: a nested case-control study[J]. Clin Transplant, 2017, 31(7). DOI: 10.1111/ctr.12983. [15] CALABRÒ ML, SARID R. Human herpesvirus 8 and lymphoproliferative disorders[J]. Mediterr J Hematol Infect Dis, 2018, 10(1): e2018061. DOI: 10.4084/MJHID.2018.061. [16] ZAFFIRI L, LONG A, NEELY ML, et al. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: analysis of ISHLT Registry[J]. J Heart Lung Transplant, 2020, 39(10): 1089-1099. DOI: 10.1016/j.healun.2020.06.010. [17] LOWERY EM, ADAMS W, GRIM SA, et al. Increased risk of PTLD in lung transplant recipients with cystic fibrosis[J]. J Cyst Fibros, 2017, 16(6): 727-734. DOI: 10.1016/j.jcf.2017.03.013. [18] BISHNOI R, MINISH J, FRANKE AJ, et al. Single-institution retrospective analysis of prognostic factors influencing very late-onset post-transplant lymphoproliferative disorder[J]. Cureus, 2020, 12(2): e6912. DOI: 10.7759/cureus.6912. [19] JAKSCH P, WIEDEMANN D, KOCHER A, et al. Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients[J]. Transplantation, 2013, 95(5): 766-772. DOI: 10.1097/TP.0b013e31827df7a7. [20] LUSTBERG ME, PELLETIER RP, PORCU P, et al. Human leukocyte antigen type and posttransplant lymphoproliferative disorder[J]. Transplantation, 2015, 99(6): 1220-1225. DOI: 10.1097/TP.0000000000000487. [21] CAZZOLA M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues[J]. Blood, 2016, 127(20): 2361-2364. DOI: 10.1182/blood-2016-03-657379. [22] LACASCE AS. Post-transplant lymphoproliferative disorders[J]. Oncologist, 2006, 11(6): 674-680. DOI: 10.1634/theoncologist.11-6-674. [23] WUDHIKARN K, HOLMAN CJ, LINAN M, et al. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota[J]. Clin Transplant, 2011, 25(5): 705-713. DOI: 10.1111/j.1399-0012.2010.01332.x. [24] GREEN M, MICHAELS MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder[J]. Am J Transplant, 2013, 13 (Suppl 3): 41-54. DOI: 10.1111/ajt.12004. [25] CRESPO-LEIRO MG, MUÑIZ J, GONZALEZ-VILCHEZ F, et al. Comment on: post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors[J]. J Heart Lung Transplant, 2016, 35(5): 693-694. DOI: 10.1016/j.healun.2016.01.006. [26] ZSCHOCHE M, ZIMPFER A, SCHEEF BO, et al. Histopathological features and Ann Arbor stage in periocular lymphoma[J]. In Vivo, 2020, 34(4): 1965-1974. DOI: 10.21873/invivo.11993. [27] MONTES DE JESUS FM, GLAUDEMANS AWJM, TISSING WJ, et al. 18F-FDG PET/CT in the diagnostic and treatment evaluation of pediatric posttransplant lymphoproliferative disorders[J]. J Nucl Med, 2020, 61(9): 1307-1313. DOI: 10.2967/jnumed.119.239624. [28] PARKER A, BOWLES K, BRADLEY JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS guidelines[J]. Br J Haematol, 2010, 149(5): 675-692. DOI: 10.1111/j.1365-2141.2010.08161.x. [29] CRAIG FE, JOHNSON LR, HARVEY SA, et al. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders[J]. Diagn Mol Pathol, 2007, 16(3): 158-168. DOI: 10.1097/PDM.0b013e31804f54a9. [30] 中华医学会器官移植学分会. 器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006.Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China(2019 edition)[J]. Organ Transplant, 2019, 10(2): 149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006. [31] FERREIRA H, BUSTORFF M, SANTOS J, et al. Post-transplant lymphoproliferative disorder: a single-center experience[J]. Transplant Proc, 2015, 47(4): 981-984. DOI: 10.1016/j.transproceed.2015.03.017. [32] VERLEDEN GM, VOS R, VANAUDENAERDE B, et al. Current views on chronic rejection after lung transplantation[J]. Transpl Int, 2015, 28(10): 1131-1139. DOI: 10.1111/tri.12579. [33] DAVIES K, BARTH M, ARMENIAN S, et al. Pediatric aggressive mature B-cell lymphomas, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(8): 1105-1123. DOI: 10.6004/jnccn.2020.0036. [34] GONZÁLEZ-BARCA E, DOMINGO-DOMENECH E, CAPOTE FJ, et al. Prospective phase Ⅱ trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease[J]. Haematologica, 2007, 92(11): 1489-1494. DOI: 10.3324/haematol.11360. [35] JAIN MD, LAM R, LIU Z, et al. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder[J]. Br J Haematol, 2020, 189(1): 97-105. DOI: 10.1111/bjh.16304. [36] MCLAUGHLIN LP, ROUCE R, GOTTSCHALK S, et al. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation[J]. Blood, 2018, 132(22): 2351-2361. DOI: 10.1182/blood-2018-07-863654. [37] KAZI S, MATHUR A, WILKIE G, et al. Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease[J]. Haematologica, 2019, 104(8): e356-e359. DOI: 10.3324/haematol.2018.207548. [38] FUNCH DP, WALKER AM, SCHNEIDER G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients[J]. Am J Transplant, 2005, 5(12): 2894-2900. DOI: 10.1111/j.1600-6143.2005.01115.x. [39] ORLANDI E, IORIO GC, BARTONCINI S, et al. Role of radiotherapy in post-transplant lymphoproliferative disorders: three case reports and review of the literature[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(4): e309-e316. DOI: 10.1016/j.clml.2020.11.006. [40] NOVOA-TAKARA L, PERKINS SL, QI D, et al. Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation[J]. Am J Clin Pathol, 2005, 123(1): 104-112. DOI: 10.1309/dw2tw2087bxl2brk. [41] HUMAR A, MICHAELS M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation[J]. Am J Transplant, 2006, 6(2): 262-274. DOI: 10.1111/j.1600-6143.2005.01207.x. [42] HUMAR A, HÉBERT D, DAVIES HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder[J]. Transplantation, 2006, 81(6): 856-861. DOI: 10.1097/01.tp.0000202724.07714.a2. -
下载:
点击查看大图
图(1) / 表(1)
计量
- 文章访问数: 391
- HTML全文浏览量: 218
- PDF下载量: 92
- 被引次数: 0
